Antabio

Antabio is a French biotech tackling the global antimicrobial resistance (AMR) crisis by developing innovative antibacterial therapies. Its most advanced asset, Meropenem-Pilabactam (MEM-PIL), is a β-lactam/β-lactamase inhibitor combination in Phase 2 development for hospital-acquired bacterial pneumonia/ventilator-associated bacterial pneumonia (HABP/VABP) and bloodstream infections (BSI). The company is backed by prominent investors like the AMR Action Fund and has a diversified early-stage pipeline targeting chronic respiratory diseases and novel bacterial targets.

Design of novel β-lactamase inhibitors and resistance-breaking agents to restore efficacy of existing antibiotics (like carbapenems) and discovery of novel antibacterial targets/chemical series.

Competition includes other biopharma companies developing next-generation β-lactam/β-lactamase inhibitor combinations (e.g., against similar carbapenemases) and novel mechanism antibiotics. Antabio differentiates by targeting a specific gap in BLI coverage (KPC/OXA) and by pursuing a diversified pipeline including a non-antibacterial virulence factor inhibitor.